Compare HKPD & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | ASBP |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | Hong Kong | United States |
| Employees | 27 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.8M |
| IPO Year | N/A | N/A |
| Metric | HKPD | ASBP |
|---|---|---|
| Price | $0.42 | $5.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 397.2K | 245.5K |
| Earning Date | 08-14-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.05 |
| 52 Week High | $2.58 | $7.05 |
| Indicator | HKPD | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 55.68 |
| Support Level | $0.34 | $0.19 |
| Resistance Level | $0.71 | $6.98 |
| Average True Range (ATR) | 0.06 | 0.95 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 35.46 | 54.72 |
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.